El-Sayed Behairy, El-Araby Hanaa, Adawy Nermin, Hassona Mona, El-Nady Naglaa, Zakaria Haidy, Khedr Mohammed
Pediatric Hepatology Department, National Liver Institute, Menofyia University, Egypt.
Clinical Pathology Department, National Liver Institute, Menofyia University, Egypt.
Clin Exp Hepatol. 2017 Sep;3(3):159-163. doi: 10.5114/ceh.2017.68399. Epub 2017 Jun 12.
To assess if elevated serum cystatin C (Cyst-C) is an indicator for renal or hepatic dysfunction in presence of liver fibrosis.
Data of 50 children with chronic liver diseases (CLDs), out of which 25 were without renal impairment, and 25 with renal impairment were analyzed. Twenty healthy children served as a healthy control group. Routine investigations, creatinine clearance, hepatitis viral markers, abdominal ultrasonography, and liver biopsy were performed for patients with CLDs. Measurement of serum Cyst-C concentration by particle induced immunonephelometry were completed for both patients and control group.
Results showed that serum Cyst-C is not correlated with the degree of hepatic impairment ( > 0.05). Cyst-C levels were significantly higher in patients with renal impairment (3.66 ± 0.85) than those without (0.71 ± 0.12), and healthy control group (0.63 ± 0.85). Cystatin-C showed significant elevation in patients with severe fibrosis with renal impairment (3.66 ± 0.85) than those without (0.76 ± 0.04) ( < 0.0001). Cyst-C at cutoff levels of 1.65 mg/l showed 100% accuracy in discrimination between those with and those without renal impairment. Cyst-C > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. Cyst-C > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%.
Serum Cyst-C is a promising marker to estimate renal impairment in children with CLDs. Further studies are needed to estimate the accuracy of serum Cyst-C for early detection of renal impairment and close monitoring of the hepatic children.
评估在存在肝纤维化的情况下,血清胱抑素C(Cyst-C)升高是否为肾或肝功能障碍的指标。
分析50例慢性肝病(CLD)患儿的数据,其中25例无肾功能损害,25例有肾功能损害。20名健康儿童作为健康对照组。对CLD患者进行常规检查、肌酐清除率、肝炎病毒标志物、腹部超声检查和肝活检。采用颗粒增强免疫比浊法完成患者和对照组血清Cyst-C浓度的测定。
结果显示血清Cyst-C与肝损害程度无关(>0.05)。肾功能损害患者的Cyst-C水平(3.66±0.85)显著高于无肾功能损害患者(0.71±0.12)和健康对照组(0.63±0.85)。与无严重纤维化的肾功能损害患者(0.76±0.04)相比,有严重纤维化的肾功能损害患者的胱抑素C显著升高(3.66±0.85)(<0.0001)。Cyst-C截断值为1.65mg/l时,区分有无肾功能损害的准确率为100%。Cyst-C>2.34mg/l预测肾小球滤过率(GFR)<40ml/min的准确率为90%。Cyst-C>2.73mg/l预测GFR<20ml/min的准确率为81.5%。
血清Cyst-C是评估CLD患儿肾功能损害的一个有前景的标志物。需要进一步研究以评估血清Cyst-C在早期检测肾功能损害及密切监测肝病患儿方面的准确性。